- Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment
- EAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-class oral antibiotic as part of GSK's industry-leading infectious diseases portfolio
GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.